October 3, 2022

Avastin No Longer FDA Approved For Breast Cancer

avastin logo

New research suggest that Avastin risks may outweigh the rewardsin breast cancer patients

On Thursday the Food and Drug Administration released a statement saying they are going to withdraw approval of Avastin as a treatment for breast cancer patients. The risks of the drug far outweigh the benefits.

The FDA approved Avastin in February 2008 to help treat late-stage breast cancer patients. The drug was supposed to slow the progression of the disease and even improve overall survival.

Since then, there have been four new trials with more than 3,000 women, and they found that there was no significant reduction in slowing the progression of the disease or reducing the number of deaths.

Dr. Janet Woodcock, who is the director of the FDA’s Center of Drug Evaluation said, “These trials were intended to confirm progression-free survival, and they did not.”

Using Avastin also comes with several risk factors such as high blood, pressure, bleeding and hemorrhaging, heart attack or heart failure and perforations in the nose, stomach and intestines.

Back in July an independent advisory committee voted 12 to 1 to withdraw the approval of Avastin for breast cancer treatment.

The drug will remain on the market to treat other cancers such as those in the brain, colon, kidney and lung. It seems to work for other types of cancers, slowing the rate of progression. Also with these other cancers, the benefits outweigh the risks. With breast cancer it’s not improving the chance of survival.

For those currently taking the drug, they should continue to do so until they are able to talk with their doctor.